Tech Company Financing Transactions

Proteostasis Therapeutics Funding Round

F-Prime Capital, Genzyme Ventures and HealthCare Ventures participated in a $45 million Series A funding round for Proteostasis Therapeutics. The round was announced on 8/25/2008.

Transaction Overview

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

80 Guest St. 5th Floor
Boston, MA 02135
USA

Phone

(617) 225-0096

Website

www.proteostasis.com

Email Address

[email protected]

Overview

Proteostasis Therapeutics (NASDAQ: PTI) is discovering and developing novel small molecule therapeutics designed to control the body's Proteostasis Network, which maintains the body's natural protein homeostasis to protect us from numerous diseases.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Meenu Chhabra

        

Chief Medical Officer

Po-Shun Lee

        

Chief Operating Officer

Marija Zecevic

        

Chief Scientific Officer

Ben Munoz

        

VP - Bus. Development

Geoffrey Gilmartin

        

VP - Operations

Sheila Wilson

        

Browse more venture capital transactions:

Prev: 8/25/2008: Demandbase venture capital transaction
Next: 8/25/2008: Sparxent venture capital transaction

Share this article

About Database of VC Transactions

We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary